Inscopix Launches Cloud-Based Platform For Data Management And Analysis To Advance Neurotherapeutic Development

IDEAS allows compilation and analysis of datasets across all R&D modalities into a single management and computing system

Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched IDEAS, a cloud-based platform for enterprises that supports the integration, organization, management and sharing of neuroscience research, data and methods to accelerate development of the next-generation of neurotherapeutics.

Recommended AI News: Nerdio Brings Significant Backup And Disaster Recovery Capabilities To Azure Virtual Desktop

Today, neuroscience groups frequently use multiple data-rich technologies, including behavioral tools, electrophysiology, 1- and 2-photon imaging, microscopy and fMRI. Effectively managing and efficiently analyzing the vast datasets collected from these technologies is a major challenge. Most data is stored in large, proprietary files within siloed locations only accessible by a single user, making the data extremely difficult to organize, retrieve, correlate, visualize or share within the lab or external collaborators. Sharing analysis workflows and dataset visualizations with other colleagues is difficult, meaning powerful insights may remain uncovered or forcing time-consuming duplication of analysis efforts. Additionally, these teams frequently need to bring in bioinformaticists to standardize and unify their data.

Inscopix’s IDEAS (Inscopix Data Exploration, Analysis and Sharing) platform is a comprehensive, secure, big data management system designed from the ground up both by and for the neuroscience community to address this significant unmet need.

“Inscopix has built a revolutionary, integrated technology which will enable scientists to create standardized, customizable push-button workflows that can analyze, store and share datasets across all modalities – from imaging to behavior to electrophysiology – and drive deeper understanding of the brain,” said Kunal Ghosh, Ph.D., CEO at Inscopix. “This artificial-intelligence-enabled (AI) platform will help researchers cut data analysis times from months to weeks or even hours; quickly share and synchronize results with colleagues; and supercharge the potential of these imaging technologies to reveal clinically-predictive and precise preclinical models for the discovery and development of the next generation of neurotherapeutics.”

Recommended AI News: Chainalysis Launches Support For The Lightning Network

IDEAS is a first-of-its-kind, turnkey, multimodal, big data platform for neuroscience research that will help:

• Store and Organize Data – The Data Library allows users to securely upload, annotate, organize, share, and store their research data and results.

• Process and Analyze Data – The Data Workbench allows users to interactively explore, control, and analyze their data and create AI-workflows using prebuilt analysis and visualization tools.

• Scale and Share Analytics – The Data Pipeline allows users to reproducibly perform high-throughput processing and analysis workflows in a fraction of the normal time, leveraging full integration with powerful cloud computing resources.

“Next-generation imaging technologies are incredibly data-rich and frequently require robust data science and analysis solutions to maximize their potential. Certainly, the powerful Inscopix imaging platform pushes those boundaries and the creation of IDEAS is a major enabling achievement from our world-class software engineering team. IDEAS is a significant advance that bridges the arc between our expertise in neuroscience imaging tools to therapeutic drug discovery,” said David Gray, Ph.D., CSO of Inscopix. “We’re excited to work with other translationally-focused collaborators to catalyze the application of novel high throughput in vivo assays with IDEAS.”

Recommended AI News: Taiwan Aims to be Global Leader in Artificial Intelligence with New AI HUB Initiative

[To share your insights with us, please write to sghosh@martechseries.com]